2. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med 2019;34:723-71.
[CROSSREF] [PUBMED] [PMC]
3. Saito Y, Teramoto T, Yamada N, Itakura H, Hata Y, Nakaya N, et al. Clinical efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the dose finding, double blind, three-group comparative study. J Clin Therap Med 2001;17:829-55.
4. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61.
[CROSSREF] [PUBMED]
5. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009;25:2755-64.
[CROSSREF] [PUBMED]
6. Kwon JE, Kim Y, Hyun S, Won H, Shin SY, Lee KJ, et al. Cholesterol lowering effects of low-dose statins in Korean patients. J Lipid Atheroscler 2014;3:21-8.
[CROSSREF]
7. Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007;29:2365-73.
[CROSSREF] [PUBMED]
8. Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation 2018;137:1997-2009.
[CROSSREF] [PUBMED] [PMC]
9. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38-81.
[CROSSREF] [PUBMED]
10. De Alava E, Sola JJ, Lozano MD, Pardo-Mindan FJ. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants. Nephron 1994;66:242-3.
[CROSSREF] [PUBMED]
11. Fernandez Zatarain G, Navarro V, Garcia H, Villatoro J, Calvo C. Rhabdomyolysis and acute renal failure associated with lovastatin. Nephron 1994;66:483-4.
[CROSSREF] [PUBMED]
12. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000;23:197-213.
[CROSSREF] [PUBMED]
13. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 1990;36:2145-7.
[CROSSREF] [PUBMED]
15. Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl 2011;12:285-8.
[CROSSREF] [PUBMED]
16. Betteridge J. Pitavastatin: results from phase III & IV. Atheroscler Suppl 2010;11:8-14.
[CROSSREF] [PUBMED]
17. Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther 2011;9:555-62.
[CROSSREF] [PUBMED]
18. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v403; Bethesda: U.S. Department of Health and Human Services, National Institutes of Health; 2010.
19. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934.
[CROSSREF] [PUBMED]
20. Cohen DE, Anania FA, Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77C-81C.
[CROSSREF] [PUBMED]
21. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
[CROSSREF] [PUBMED]
22. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006;97(8A):32C-43C.
[CROSSREF] [PUBMED]
23. Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018;15:757-69.
[CROSSREF] [PUBMED]
24. Sylvain-Moore H, Worden JP Jr. Lovastatin-associated rhabdomyolysis. Heart Lung 1991;20(5 Pt 1):464-6.
[PUBMED]
25. Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993;52:542-9.
[CROSSREF] [PUBMED]
26. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992;26:190-2.
[CROSSREF] [PUBMED]
27. Hume AL. Comment: lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992;26:1303.
[CROSSREF] [PUBMED]
28. Pedro-Botet J, Nunez-Cortes JM, Flores JA, Rius J. Muscle symptoms related with statin therapy in general practice. Atherosclerosis 2015;241:e197.
[CROSSREF]
29. Khan A, Maki KC, Ito MK, Cohen JD, Sponseller CA, Bell M, et al. Statin associated muscle symptoms: characteristics of patients and recommendations by providers. J Clin Lipidol 2015;9:460.
[CROSSREF]
30. Crouse JR, Grundy SM. Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. J Lipid Res 1984;25:486-96.
[CROSSREF] [PUBMED]
31. Wakabayashi I. Alcohol intake and triglycerides/high-density lipoprotein cholesterol ratio in men with hypertension. Am J Hypertens 2013;26:888-95.
[CROSSREF] [PUBMED]
32. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
[CROSSREF] [PUBMED]
33. Betteridge DJ, Carmena R. The diabetogenic action of statins: mechanisms and clinical implications. Nat Rev Endocrinol 2016;12:99-110.
[CROSSREF] [PUBMED]
34. Choi SH, Lim S, Hong ES, Seo JA, Park CY, Noh JH, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol (Oxf) 2015;82:670-7.
[CROSSREF] [PUBMED]
35. Jeong HS, Hong SJ, Son S, An H, Kook H, Joo HJ, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol 2019;18:162.
[CROSSREF] [PUBMED] [PMC]
36. Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, et al. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol 2018;122:922-8.
[CROSSREF] [PUBMED]